---
title: "Benchmarking frontier LLMs on 1,477 hematology board-style MCQs: accuracy and failure patterns"
id: "medrxiv-1-benchmarking-ten-frontier-large-language-models-on-1-477-board-style-multiple"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-benchmarking-ten-frontier-large-language-models-on-1-477-board-style-multiple"
content_type: "clinical_feed_article"
specialty: "Hematology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Benchmarking frontier LLMs on 1,477 hematology board-style MCQs: accuracy and failure patterns
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-benchmarking-ten-frontier-large-language-models-on-1-477-board-style-multiple
- **Specialty:** [Hematology](https://medichelpline.com/clinical-feed/hematology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Researchers benchmarked ten leading large language models (LLMs) on 1,477 board-style multiple-choice questions (MCQs) in hematology drawn from five publicly available educational datasets spanning nine disease areas and six clinical skill domains. - Models included both proprietary and open-weight LLMs across two generations; testing covered text-only and multimodal case vignettes. - Top mean accuracies on text-only items were achieved by **Claude Opus 5** (92.7%), **Gemini-3.1 Pro** (91.4%), **Gemini-3.6 Flash** (91.0%) and **GPT-5.6 Sol** (89.9%). - On multimodal items, reported mean accuracies for these models were lower: Claude Opus 5 (76.9%), Gemini-3.1 Pro (78.7%), Gemini-3.6 Flash (74.8%) and GPT-5.6 Sol (76.7%). - Accuracy correlated significantly with **model size** for both text-only and multimodal MCQs. - Performance gains between model generations were largest for open-weight models; proprietary models showed only marginal generational improvements. - Error analysis revealed that top-performing models shared highly concordant failure patterns, indicating common limitations on challenging cases rather than idiosyncratic errors. - Authors conclude frontier LLMs demonstrate substantial specialist **hematology** knowledge across subspecialties and clinical skills, but caution that continuous expert-on-the-loop monitoring is essential despite high accuracy on board-style questions. - Data sources used were publicly available BSH MCQ, BSH EMQ, BSH Case Reports, ASH Hematopoiesis Case Studies, and EBMT Case of the Month; no new patient data or identifiable information were used. - Funding was declared from German Cancer Aid; competing interests by several authors were reported as detailed in the source.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Benchmarking ten frontier large language models on 1,477 board style multiple choice questions in hematology [ View ORCID Profile](http://orcid.org/0009-0003-4358-0391)Martina Radoynova, [ View ORCID Profile](http://orcid.org/0000-0002-9107-9329)Mohamed Benouis, [ View ORCID Profile](http://orcid.org/0009-0001-7833-5869)freya schulze, [ View ORCID Profile](http://orcid.org/0000-0002-4228-4537)Susann Winter, [ View ORCID Profile](http://orcid.org/0000-0002-5916-3029)MartiN Bornhauser, [ View ORCID Profile](http://orcid.org/0000-0003-3250-293X)Jan Moritz Middeke, [ View ORCID Profile](http://orcid.org/0000-0002-3649-2823)Jan-Niklas Eckardt doi: https://doi.org/10.64898/2026.09.01.26361881 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Martina Radoynova 1 Department of Internal Medicine I University Hospital Carl Gustav Carus TUD Dresden University of Technology; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Martina%2BRadoynova%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Radoynova%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMartina%2BRadoynova%2B) * [ORCID record for Martina Radoynova](http://orcid.org/0009-0003-4358-0391 "Open in new tab") Mohamed Benouis 2 University Hospital Carl Gustav Carus TUD Dresden University of Te; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mohamed%2BBenouis%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Benouis%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMohamed%2BBenouis%2B) * [ORCID record for Mohamed Benouis](http://orcid.org/0000-0002-9107-9329 "Open in new tab") freya schulze 3 Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=freya%2Bschulze%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=schulze%20F&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3Afreya%2Bschulze%2B) * [ORCID record for freya schulze](http://orcid.org/0009-0001-7833-5869 "Open in new tab") Susann Winter 4 Department of Internal Medicine I University Hospital Carl Gustav Carus TUD Dresden University of Technology, Dresden, Germany * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Susann%2BWinter%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Winter%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASusann%2BWinter%2B) * [ORCID record for Susann Winter](http://orcid.org/0000-0002-4228-4537 "Open in new tab") MartiN Bornhauser 4 Department of Internal Medicine I University Hospital Carl Gustav Carus TUD Dresden University of Technology, Dresden, Germany * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=MartiN%2BBornhauser%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bornhauser%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AMartiN%2BBornhauser%2B) * [ORCID record for MartiN Bornhauser](http://orcid.org/0000-0002-5916-3029 "Open in new tab") Jan Moritz Middeke 4 Department of Internal Medicine I University Hospital Carl Gustav Carus TUD Dresden University of Technology, Dresden, Germany * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jan%2BMoritz%2BMiddeke%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Middeke%20JM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJan%2BMoritz%2BMiddeke%2B) * [ORCID record for Jan Moritz Middeke](http://orcid.org/0000-0003-3250-293X "Open in new tab") Jan-Niklas Eckardt 4 Department of Internal Medicine I University Hospital Carl Gustav Carus TUD Dresden University of Technology, Dresden, Germany * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jan-Niklas%2BEckardt%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Eckardt%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJan-Niklas%2BEckardt%2B) * [ORCID record for Jan-Niklas Eckardt](http://orcid.org/0000-0002-3649-2823 "Open in new tab") * For correspondence: jan-niklas.eckardt@ukdd.de * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1290677/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1290677/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1290677/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1290677/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1290677/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Large Language Models (LLMs) are increasingly used by clinicians and patients for medical queries, yet their accuracy and safety at the specialist level in hematology remain insufficiently characterised. We benchmarked ten frontier proprietary and open-weight LLMs across two generations on 1,477 board-style hematology multiple-choice questions (MCQs) derived from five educational datasets spanning nine disease areas and six clinical skill domains, including text-only and multimodal case vignettes. Claude Opus 5 had the highest mean accuracy (92.7% text, 76.9% multimodal), followed closely by Gemini-3.1 Pro (91.4% and 78.7%), Gemini-3.6 Flash (91.0% and 74.8%) and GPT-5.6 Sol (89.9% and 76.7%). Accuracy significantly correlated with model size both for text-only and multimodal MCQs. Between model generations, the largest improvements in accuracy were seen for open-weight models whereas proprietary models showed only marginal gains. In error analysis, top-performing models exhibited highly concordant failure patterns, suggesting shared limitations on challenging cases. Frontier LLMs exhibit substantial specialist hematology knowledge across diverse subspecialist domains and clinical skill sets. Yet, despite high accuracy on board-style questions in hematology, continuous expert-on-the-loop output monitoring is paramount. ### Competing Interest Statement MB has received honoraria from Astellas and Onkowissen.de and has acted on advisory boards for Jazz and ActiTrexx. He is employed by the University Hospital of TU Dresden and is a co-speaker of the Study Alliance Leukemia. JMM declares consulting services for Janssen, Roche, Gilead, Abbvie, Jazz, Pfizer, Astellas, Novartis, AstraZeneca and Glycostem. Furthermore, he holds shares in Cancilico and Synagen; has received institutional research grants from Janssen, Jazz and Novartis; and has received honoraria from Novartis, Roche, Janssen, Abbvie, Pfizer, Sanofi, Astellas and Beigene. J-NE declares consulting services for AstraZeneca, Novartis, and Johnson & Johnson, holds shares in Cancilico, has received an institutional research grant by Novartis and has received honoraria by Astellas, Amgen, AstraZeneca, Johnson & Johnson, Novartis, Servier and Pfizer. The other authors declare no competing interests. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study used only openly available educational datasets that were publicly accessible before the study began. The data sources were: British Society for Haematology Multiple-Choice Questions: https://b-s-h.org.uk/education/bsh-education-resources/multiple-choice-questions British Society for Haematology Extended Matching Questions: https://b-s-h.org.uk/education/bsh-education-resources/extended-matching-questions British Society for Haematology Case Reports: https://b-s-h.org.uk/education/bsh-education-resources/case-reports American Society of Hematology Hematopoiesis Case Studies: https://www.hematology.org/education/trainees/fellows/case-studies European Society for Blood and Marrow Transplantation Case of the Month: https://www.ebmt.org/ebmt/news?combine=clinical+case No participants were recruited, no new patient data were collected, and the study authors did not access identifiable or controlled-access patient-level data. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All datasets used for benchmarking are publicly available from BSH-MCQ (https://b-s-h.org.uk/education/bsh-education-resources/multiple-choice-questions), BSH-EMQ (https://b-s-h.org.uk/education/bsh-education-resources/extended-matching-questions), BSH Case Reports (https://b-s-h.org.uk/education/bsh-education-resources/case-reports), ASH Hematopoiesis Case Studies (https://www.hematology.org/education/trainees/fellows/case-studies), and EBMT Case of the Month (https://www.ebmt.org/ebmt/news?combine=clinical+case). ## Funder Information Declared German Cancer Aid, 70117128 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.31.26361856v1 "Social Determinants of Health in HIV/HBV Coinfection Compared with HIV and HBV Monoinfection: A Framework for Dynamic Social Vulnerability")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.01.26361874v1 "Can Dental AI Really Beat Dentists? DentalPair-Cert for Rigorous AI-Dentist Inference") Posted September 02, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/02/2026.09.01.26361881.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.01.26361881v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/02/2026.09.01.26361881.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Benchmarking ten frontier large language models on 1,477 board style multiple choice questions in hematology Martina Radoynova, Mohamed Benouis, freya schulze, Susann Winter, MartiN Bornhauser, Jan Moritz Middeke, Jan-Niklas Eckardt medRxiv 2026.09.01.26361881; doi: https://doi.org/10.64898/2026.09.01.26361881 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.01.26361881v1%26text%3DBenchmarking%2520ten%2520frontier%2520large%2520language%2520models%2520on%25201%252C477%2520board%2520style%2520multiple%2520choice%2520questions%2520in%2520hematology "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.01.26361881v1%26t%3DBenchmarking%2520ten%2520frontier%2520large%2520language%2520models%2520on%25201%252C477%2520board%2520style%2520multiple%2520choice%2520questions%2520in%2520hematology "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.01.26361881v1%26title%3DBenchmarking%2520ten%2520frontier%2520large%2520language%2520models%2520on%25201%252C477%2520board%2520style%2520multiple%2520choice%2520questions%2520in%2520hematology%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.01.26361881v1%26title%3DBenchmarking%2520ten%2520frontier%2520large%2520language%2520models%2520on%25201%252C477%2520board%2520style%2520multiple%2520choice%2520questions%2520in%2520hematology "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.01.26361881) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.01.26361881v1&count=horizontal&via=&text=Benchmarking%20ten%20frontier%20large%20language%20models%20on%201%2C477%20board%20style%20multiple%20choice%20questions%20in%20hematology&counturl=www.medrxiv.org/content/10.64898/2026.09.01.26361881v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (614) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (896) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (327) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4772) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (475) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (408) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (643) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1615) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15839) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1195) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6984) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (727) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1057) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4989) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1427) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1738) * [Hematology](https://www.medrxiv.org/collection/hematology) (583) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1337) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16246) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.or
## Related Clinical Research

- [Strategies to Improve Access to HIV Services for Children in Malawi: Study Protocol](https://medichelpline.com/clinical-feed/plos-one-23-investigating-strategies-to-enhance-access-to-hiv-services-among-children-in.md)
- [Which interventions affect biological aging? Epigenetic study finds diet, exercise, and some drugs](https://medichelpline.com/clinical-feed/medical-news-today-0-what-can-and-can-t-slow-down-aging-new-study-offers-clues.md)
- [Intensive blood pressure control linked to 15% lower 7-year dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-intensive-blood-pressure-control-cuts-7-year-dementia-risk-by-15-study-finds.md)
- [Health and Economic Impact of Scaling Monthly Oral PrEP (MK-8527) Versus Injectable Lenacapavir in](https://medichelpline.com/clinical-feed/medrxiv-10-modeling-the-health-and-economic-impact-of-scaling-up-monthly-oral-pre-exposure.md)
- [Human-Centered Design to Identify and Reach Zero-Dose and Under-Immunized Children in Kenya](https://medichelpline.com/clinical-feed/medrxiv-8-applying-human-centered-design-and-iterative-programming-to-identify-and-reach.md)

## Navigation
- [← Back to Hematology Feed](https://medichelpline.com/clinical-feed/hematology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.